Junyan Lyu, Hikari Okada, Hajime Sunagozaka, Kazunori Kawaguchi, Tetsuro Shimakami, Kouki Nio, Kazuhisa Murai, Takayoshi Shirasaki, Mika Yoshida, Kuniaki Arai, Tatsuya Yamashita, Takuji Tanaka, Kenichi Harada, Toshinari Takamura, Shuichi Kaneko, Taro Yamashita, Masao Honda
BACKGROUND: Recent reports have unveiled the potential utility of l-carnitine to alleviate metabolic dysfunction-associated steatohepatitis (MASH) by enhancing mitochondrial metabolic function. However, its efficacy at preventing the development of HCC has not been assessed fully. METHODS: l-carnitine (2 g/d) was administered to 11 patients with MASH for 10 weeks, and blood liver function tests were performed. Five patients received a serial liver biopsy, and liver histology and hepatic gene expression were evaluated using this tissue...
May 1, 2024: Hepatology Communications